$RGNX

Regenxbio

$RGNX

Regenxbio

Past 12mo:17mentions2voices

All voices5 calls since Jan 2026show all

Loading price chart…

About this stock

Over the past 12 months, $RGNX has generated 17 mentions from 2 distinct FinTwit voices, with coverage beginning on 2025-10-08. The biotech specialist @adamfeuerstein (@adamfeuerstein) accounts for 16 of these mentions, establishing himself as the dominant voice discussing Regenxbio. @investmentguru_ contributed 1 mention. Recent discussion has centered on FDA regulatory developments, with posts from late June 2026 highlighting shifts in the agency's approach to the company's gene therapy programs.

AI-generated from tracked posts · updated Aug 16, 2026

Frequently asked

Related stocks

$ALKSAlkermes

$ALMSAlumis

$ASNDAscendis Pharma A/S

$ATAIATAI Life Sciences

Recent calls

5 calls

@adamfeuersteinJun 24, 2026 · 12:14 PM

Wagering on FDA changes, Regenxbio $RGNX will submit Duchenne gene therapy for approval https://t.co/VeVHWXu903 via @Jasonmmast

Open on X

@adamfeuersteinJun 22, 2026 · 10:44 AM

FDA reverses course on Regenxbio’s $RGNX childhood gene therapy after rejection https://t.co/VoNaSAZ4wm via @Jasonmmast

Open on X

@adamfeuersteinMay 14, 2026 · 11:07 AM

$RGNX Duchenne gene therapy study results are out: microdystrophin expression reached an average of 71% of normal across all 31 boys at 12 wks. Functional improvements in a subset of boys followed for one year also seen. The big question remains: Will the FDA still follow the $SRPT precedent and grant accelerated approval to the Regenxbio gene therapy? CEO Curran Simpson told me the company is holding off on submitting to the FDA until early next year. “I think our data checks every single box that you would want for accelerated approval,” he told me. "We’re not in a rush to go to the FDA at this point. We want to give time for the leadership changes to occur. But that’s OK, because we can still meet our timeline of securing an approval in 2027." More details in our story, written with @Jasonmmast in the following post.

Open on X

@adamfeuersteinFeb 9, 2026 · 9:26 PM

FDA rejects Regenxbio’s $RGNX rare-disease gene therapy Agency raised questions about the surrogate biomarker used to predict clinical benefit in Hunter syndrome https://t.co/LZSIHMMe73

Open on X

@adamfeuersteinJan 28, 2026 · 12:33 PM

BREAKING: FDA halts $RGNX gene therapy trials after brain tumor found in patient. Tumor found in patient treated with MPS I therapy. FDA placed hold on it and the MPS II therapy. They are similar constructs. The MPS II therapy has a Feb. 8 PDUFA date, now up in the air. https://t.co/oU23gsA5G2 via @Jasonmmast

Open on X

Who mentions $RGNX most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $RGNX most — 16 mentions in the past 12 months.

When was $RGNX first mentioned on Surfaced?

The earliest tracked mention of $RGNX in the Surfaced archive was on Oct 8, 2025.

How many voices track $RGNX?

2 FinTwit voices have mentioned $RGNX 17 times in the past 12 months.

What kind of voices mention $RGNX most?

$RGNX is mentioned most by Biotech voices on Surfaced.